CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) Sees Large Decline in Short Interest

CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) was the recipient of a significant decrease in short interest during the month of July. As of July 15th, there was short interest totaling 16,240 shares, a decrease of 51.8% from the June 30th total of 33,721 shares. Based on an average daily trading volume, of 29,266 shares, the short-interest ratio is currently 0.6 days. Approximately 0.1% of the company’s stock are short sold.

CollPlant Biotechnologies Stock Up 2.6%

Shares of NASDAQ:CLGN traded up $0.01 on Thursday, reaching $0.32. The company had a trading volume of 7,939 shares, compared to its average volume of 79,092. The stock has a market capitalization of $4.62 million, a P/E ratio of -0.22 and a beta of 1.60. The stock has a 50-day moving average price of $0.36 and a 200 day moving average price of $0.62. CollPlant Biotechnologies has a twelve month low of $0.27 and a twelve month high of $3.23.

CollPlant Biotechnologies (NASDAQ:CLGN) last issued its quarterly earnings data on Saturday, May 30th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. CollPlant Biotechnologies had a negative return on equity of 218.81% and a negative net margin of 683.68%.The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.46 million.

Hedge Funds Weigh In On CollPlant Biotechnologies

An institutional investor recently raised its position in CollPlant Biotechnologies stock. Villere ST Denis J & Co. LLC increased its position in shares of CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) by 3.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 607,300 shares of the company’s stock after buying an additional 18,583 shares during the period. Villere ST Denis J & Co. LLC owned 4.75% of CollPlant Biotechnologies worth $850,000 at the end of the most recent reporting period. 21.69% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of CollPlant Biotechnologies from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, June 8th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $11.50.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.